Search Within

Advanced Practice Providers

  1. "Isabelle Riviere"
Formats
  1. Meeting Abstract (29)
  2. Journal Article (9)
  3. Research Letter (1)
Groups
  1. Department of Medicine (39)
  2. Hematologic Malignancies, Division of (39)
  3. Center for Hematologic Malignancies (38)
  4. GSK Faculty (38)
  5. Hematologic Malignancies Research (38)
  6. Adult Leukemia (37)

More Groups

People
  1. Isabelle Riviere (39)
  2. Renier Brentjens (35)
  3. Elizabeth Halton (33)
  4. Jae Park (33)
  5. Michel Sadelain (31)
  6. Xiuyan Wang (29)

More People

Years
  1. 2023 (1)
  2. 2022 (3)
  3. 2021 (5)
  4. 2020 (2)
  5. 2019 (6)
  6. 2018 (7)

More Years

Publications
  1. Blood (15)
  2. Journal of Clinical Oncology (9)
  3. Molecular Therapy (3)
  4. Cancer Discovery (2)
  5. Cancer Research (1)
  6. Gynecologic Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (15)
  2. American Society of Clinical Oncology (9)
  3. Nature Publishing Group (5)
  4. American Association for Cancer Research (3)
  5. Amer Soc Clinical Investigation Inc (1)
  6. American Association for the Advancement of Science (1)

More Publishers

Results (39)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC)
    Meeting Abstract

    O'Cearbhaill, R. E.; Park, J. H.; Halton, E. F.; Diamonte, C. R.; Mead, E.; Lakhman, Y.; Kane, P.; Riviere, I. C.; Brentjens, R. J.
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Clinical factors associated with improved survival following allogeneic HSCT after CD19 CAR therapy in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J. H.; Flynn, J.; Gonen, M.; Bernal, Y.; Diamonte, C.; Halton, E.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R. J.
    Blood (2019)

    Fulltext@MSK | Save
  • Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL
    Meeting Abstract

    Perica, K.; Flynn, J.; Curran, K. J.; Wang, X.; Halton, E.; Diamonte, C.; Pineda, J.; Bernal, Y.; Gonen, M.; Riviere, I.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent
    Meeting Abstract

    Adusumilli, P. S.; Zauderer, M. G.; Rusch, V. W.; O'Cearbhaill, R.; Zhu, A.; Ngai, D.; McGee, E.; Chintala, N.; Messinger, J.; Cheema, W.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy
    Meeting Abstract

    Adusumilli, P. S.; Zauderer, M. G.; Rusch, V. W.; O'Cearbhaill, R. E.; Zhu, A.; Ngai, D. A.; McGee, E.; Chintala, N. K.; Messinger, J. C.; Vincent, A.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Phase I clinical trial of CD19‐targeted 19‐28z/4‐1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter transformation
    Meeting Abstract

    Batlevi, C. L.; Palomba, M. L.; Park, J.; Mead, E.; Santomasso, B.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R.; Yang, J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
    Journal Article

    Geyer, M. B.; Riviere, I.; Senechal, B.; Wang, X.; Wang, Y.; Purdon, T. J.; Hsu, M.; Devlin, S. M.; Palomba, M. L.; Halton, E.; more...
    JCI Insight (2019)

    Fulltext@MSK | Save
  • A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter's transformation
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Batlevi, C. L.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R. R.; Bernal, Y.; Hall, M.; Pineda, J.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial
    Meeting Abstract

    Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Intestinal microbiota composition prior to CAR T cell infusion correlates with efficacy and toxicity
    Meeting Abstract

    Smith, M.; Littmann, E. R.; Slingerland, J. B.; Clurman, A.; Slingerland, A. E.; Taur, Y.; Schluter, J.; Park, J. H.; O'Cearbhaill, R.; Mailankody, S.; more...
    Blood (2018)

    Fulltext@MSK | Save